详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Natural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, 610041, China [2]State Key Laboratory of Southwestern Chinese Medicine Resources, The Ministry of Education Key Laboratory of Standardization of Chinese Herbal Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China [3]Laboratory of Biotherapy, National Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China [4]University of Chinese Academy of Sciences, Beijing, 100049, China

出处：

DOI：

ISSN：

关键词： Human tyrosinase Cereblon E3 ubiquitin ligase PROTAC Pigmentary skin disorders

摘要：

The human tyrosinase is the most prominent therapeutic target for pigmentary skin disorders. However, the overwhelming majority efforts have been devoted to search mushroom tyrosinase inhibitors, which show poor inhibitory activity on human tyrosinase and certain side effects that cause skin damage in practical application. Herein, a series of degraders that directly targeted human tyrosinase was firstly designed and synthesized based on newly developed PROTAC technology. The best PROTAC TD9 induced human tyrosinase degradation obviously in dose and time-dependent manner, and its mechanism of inducing tyrosinase degradation has also been clearly demonstrated. Besides, encouraging results that low-toxicity PROTAC TD9 was applied to reduce zebrafish melanin synthesis have been obtained, highlighting the potential to treatment of tyrosinase-related disorders. Moreover, this work has innovatively expanded the application scope of PROTAC technology and laid a solid foundation for further development of novel drugs treating pigmentary skin disorders.Copyright © 2021. Published by Elsevier Masson SAS.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区药物化学

最新[2023]版：

大类 | 2 区

医学

小类 | 1 区药物化学

第一作者：

第一作者机构： [1]Natural Products Research Center, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, 610041, China [4]University of Chinese Academy of Sciences, Beijing, 100049, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma [2]Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles [3]Development of selective mono or dual PROTAC degrader probe of CDK isoforms. [4]Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation [5]Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1 [6]A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. [7]Editorial: The challenge of immunity evaluation and immunotherapy in gynecologic and urologic oncology [8]Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors [9]Targeted Protein Degradation: An Important Tool for Drug Discovery for "Undruggable" Tumor Transcription Factors [10]医院后勤精细化管理策略研究